Cochrane · systematic review · CD010984
Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation
Estcourt, LJ, Stanworth, S, Doree, C, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
10
No studies
3
Included studies
NR
No studies 3 · 14.3%Ungraded 8 · 38.1%Very low 0 · 0%Low 7 · 33.3%Moderate 3 · 14.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Prophylactic platelet transfusions with low‐dose schedule compared to prophylactic platelet transfusions with standard‐dose schedule for people with a haematological disorder
Population: People with a haematological disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule | RR 1.04 [0.95, 1.13] | 4 studies · 1170 participants | Moderate Downgraded: risk of bias |
Number of days on which bleeding occurred per participant up to 30 days from study entry Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule | no estimate extracted | 2 studies · 230 participants | Low Downgraded: risk of bias, imprecision |
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule | RR 1.33 [0.91, 1.92] | 3 studies · 1059 participants | Low Downgraded: risk of bias, imprecision |
Time to first bleeding episode (days) Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule | no estimate extracted | 2 studies · 959 participants | Ungraded |
Number of platelet transfusions per participant up to 30 days from study entry Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule | no estimate extracted | 3 studies · 1070 participants | Ungraded |
Mortality from all causes up to 30 days from study entry Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule | RR 2.04 [0.7, 5.93] | 3 studies · 1070 participants | Low Downgraded: risk of bias, imprecision |
Quality of life ‐ not reported Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule | no estimate extracted | NR | No studies |
Prophylactic platelet transfusions with low‐dose schedule versus high‐dose schedule for preventing bleeding in people with haematological disorders after chemotherapy or stem cell transplantation
Population: People with a haematological disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule | RR 1.02 [0.93, 1.11] | 1 study · 849 participants | Moderate Downgraded: risk of bias |
Number of days on which bleeding occurred per participant up to 30 days from study entry Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule | no estimate extracted | 1 study · 849 participants | Ungraded |
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule | RR 1.2 [0.82, 1.77] | 1 study · 849 participants | Low Downgraded: risk of bias |
Time to first bleeding episode Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule | no estimate extracted | 1 study · 849 participants | Ungraded |
Mortality from all causes up to 30 days from study entry Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule | RR 1.33 [0.5, 3.54] | 1 study · 849 participants | Low Downgraded: risk of bias |
Number of platelet transfusions per participant Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule | no estimate extracted | 1 study · 849 participants | Ungraded |
Quality of life ‐ not reported Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule | no estimate extracted | NR | No studies |
Prophylactic platelet transfusions with high‐dose schedule versus standard‐dose schedule for preventing bleeding in people with haematological disorders after chemotherapy or stem cell transplantation
Population: People with a haematological disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule | RR 1.02 [0.93, 1.11] | 2 studies · 951 participants | Moderate Downgraded: risk of bias |
Number of days on which bleeding occurred per participant up to 30 days from study entry Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule | no estimate extracted | 1 study · 855 participants | Ungraded |
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule | RR 1.11 [0.73, 1.68] | 1 study · 855 participants | Low Downgraded: risk of bias |
Time to first bleeding episode (days) Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule | no estimate extracted | 1 study · 855 participants | Ungraded |
Number of platelet transfusions per participant up to 30 days from study entry Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule | no estimate extracted | 3 studies · 1005 participants | Ungraded |
Mortality from all causes up to 30 days from study entry Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule | RR 1.71 [0.51, 5.81] | 1 study · 855 participants | Low Downgraded: risk of bias |
Quality of life ‐ not reported Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose schedule | no estimate extracted | NR | No studies |